Type 2 diabetes: Personalizing therapy.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 888, doi. 10.1038/nrd4499
- By:
- Publication type:
- Article
Works matching IS 14741776 AND DT 2014 AND VI 13 AND IP 12
Results: 24
1
2
New drugs cost US$2.6 billion to develop.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 877, doi. 10.1038/nrd4507
- By:
- Publication type:
- Article
3
Targeting RAS-ERK signalling in cancer: promises and challenges.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 928, doi. 10.1038/nrd4281
- By:
- Publication type:
- Article
4
Cancer: New delivery platform targets antimirs to tumours.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 888, doi. 10.1038/nrd4493
- By:
- Publication type:
- Article
5
Is there new hope for therapeutic matrix metalloproteinase inhibition?
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 904, doi. 10.1038/nrd4390
- By:
- Publication type:
- Article
6
Sepsis: PCSK9 blockade helps clear pathogenic lipids.
- Published in:
- 2014
- By:
- Publication type:
- journal article
7
Phase III setback for lead angiopoietin inhibitor.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 877, doi. 10.1038/nrd4509
- By:
- Publication type:
- Article
8
Natural products: Global classification of NPGCs.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 888, doi. 10.1038/nrd4500
- By:
- Publication type:
- Article
9
Doug Williams.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 880, doi. 10.1038/nrd4496
- Publication type:
- Article
10
Drug discoverers chart path to tackling data irreproducibility.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 875, doi. 10.1038/nrd4488
- By:
- Publication type:
- Article
11
European regulators approve first PARP inhibitor.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 877, doi. 10.1038/nrd4508
- By:
- Publication type:
- Article
12
SCF ubiquitin ligase-targeted therapies.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 889, doi. 10.1038/nrd4432
- By:
- Publication type:
- Article
13
Breakthrough programme turns two.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 873, doi. 10.1038/nrd4487
- By:
- Publication type:
- Article
14
A novel approach for establishing cardiovascular drug efficacy.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 942, doi. 10.1038/nrd4090-c2
- By:
- Publication type:
- Article
15
Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 879, doi. 10.1038/nrd4502
- By:
- Publication type:
- Article
16
Obesity: Adenosine protects from diet-induced obesity.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 886, doi. 10.1038/nrd4490
- By:
- Publication type:
- Article
17
Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 878, doi. 10.1038/nrd4468
- By:
- Publication type:
- Article
18
Neurodegenerative disease: New dimensions in Alzheimer's modelling.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 887, doi. 10.1038/nrd4494
- By:
- Publication type:
- Article
19
Metabolic disease: Mitochondrial uncoupler reverses diabetes.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 885, doi. 10.1038/nrd4491
- By:
- Publication type:
- Article
20
Type 2 diabetes: New lipid class regulates glucose homeostasis.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 888, doi. 10.1038/nrd4501
- By:
- Publication type:
- Article
21
Securing the future of drug discovery for central nervous system disorders.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 871, doi. 10.1038/nrd4489
- Publication type:
- Article
22
Trial watch: Self-inactivating gene-therapy vector alleviates safety concerns.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 879, doi. 10.1038/nrd4495
- By:
- Publication type:
- Article
23
The immune checkpoint inhibitors: where are we now?
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 883, doi. 10.1038/nrd4476
- By:
- Publication type:
- Article
24
Metabolic disease: Weight loss herb targets GPCR.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 888, doi. 10.1038/nrd4498
- By:
- Publication type:
- Article